Adaptive Biotechnologies (ADPT) Capital Expenditures Growth (3y) (2021 - 2026)
Adaptive Biotechnologies (ADPT) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 16.58% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | -6.49% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 93.09% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 10.06% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 7.36% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | -3.55% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | -5.23% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | -1.12% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 8.41% |
| 10 | Adaptive Biotechnologies | 4.23 Bn | 3.89 Bn | 51.39 Mn | -31.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.58% |
| Mar 31, 2026 | -35.19% |
| Dec 31, 2025 | -36.99% |
| Sep 30, 2025 | -57.77% |
| Jun 30, 2025 | -50.18% |
| Mar 31, 2025 | -25.76% |
| Dec 31, 2024 | -79.47% |
| Sep 30, 2024 | -71.34% |
| Jun 30, 2024 | -57.19% |
| Mar 31, 2024 | -54.31% |
| Dec 31, 2023 | -48.26% |
| Sep 30, 2023 | -12.92% |
| Jun 30, 2023 | 17.78% |
| Mar 31, 2023 | -0.44% |
| Dec 31, 2022 | 1.71% |
| Sep 30, 2022 | 16.56% |
| Jun 30, 2022 | 51.52% |
| Mar 31, 2022 | -7.05% |
| Dec 31, 2021 | 54.74% |
| Sep 30, 2021 | 88.29% |